Ann: Paradigm to Present at Evercore ISI HealthCONx Conference, page-158

Mozz, once again, we know what the drug is and how it works. This is no lotto ticket, and anyone referring to it as such doesn't have a clue, which is the reason I didn't directly respond to that earlier comment.

This is not about the drug, how it works or what the future potential is down the track.

This is about information that Paul has said that has blindsided us all. Your quote from PAR today and Paul's verbal quotes at the bio-conference on Friday are contradictory. It's cleared nothing up, and it only creates more uncertainty and questions.

Soooo...I say it again...

If PAR aren't yet aware of the FDA feedback, as stated in the quote that you (Mozz) posted, then where has PR plucked "2024" and the additional trial recipient numbers from?

That's price sensitive news that wasn't officially released to market via an ASX announcement. I have a real problem with that. Others do too. I am pretty sure the ASX would as well.

It can't just be explained away with an, "Oh well, we have an AMAZING, life-changing, block-buster drug, what's a couple more years?!"

This matters! It is NOT about the drug, what it can do, what it could possibly become or who it could possibly help. The rose-coloured glasses need to come off and it needs to be called out for what it is! A complete and utter balls-up!

Why does it matter so much? What's a couple of years? This changes the current and future price trajectory. This changes who is in and who is out. This changes our cash on hand, and if there will be enough to see us through to the end. Will the extended timeline mean that a future CR is possible? A future CR means further dilution.

The myriad of variables and repercussions going forward spreads far and wide. I could go on, but I've made my point quite clearly, both here and in previous posts.